Relation between Blood Pressure Management and Renal Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Patients with Chronic Kidney Disease

Table 2

Delta changes in parameters of blood pressure and diabetes control.

	BP (mmHg) at initiation of SGLT2i treatment
	Well-controlled group ()	Poorly controlled group ()	value
Δlogarithmic value of ACR			n.s.
ΔeGFR (ml/min/1.73 m^2)			0.007
ΔCCR (ml/min)			0.016
ΔHbA1c (mmol/mol) (%)			0.023
ΔBW (kg)			n.s.
ΔSBP/ΔDBP at office (mmHg)			<0.001/<0.001
ΔMAP at office (mmHg)			<0.001
	MAP (mmHg) at the time of the survey
	<102 ()	≥102 ()	value
Δlogarithmic value of ACR			<0.001
ΔeGFR (ml/min/1.73 m^2)			n.s.
ΔCCR (ml/min)			n.s.
ΔHbA1c (mmol/mol) (%)			n.s.
ΔBW (kg)			0.004
ΔSBP/ΔDBP at office (mmHg)			<0.001/<0.001
ΔMAP at office (mmHg)			<0.001

Abbreviations: ACR: urinary albumin-creatinine ratio; BW: body weight; CCR: creatinine clearance, calculated by the Cockcroft-Gault formula; DBP: diastolic blood pressure; Δ: change in; eGFR: estimated glomerular filtration rate; HbA_1c: hemoglobin A_1c; MAP: mean arterial pressure; n.s.: not significant; SGLT2i: sodium-glucose cotransporter 2 inhibitors; SBP: systolic blood pressure.